ClinicalTrials.gg

Program

JMKX000197

A development code.

Its studies are mostly in Pleural Effusion, Malignant, led by 2 companies.

Furthest: phase 2, since May 23, 20233 company-led studies, 3 open or runningNext primary completion: Jan 12, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jemincare22 open or runningphase 1since May 23, 2023May 23, 2023none ahead
Shanghai Jeyou Pharmaceutical11 open or runningphase 2since Jun 10, 2026Jun 10, 2026Jan 12, 2028phase 2 · NCT07649369

Also a collaborator on its studies: zhejiang-hangyu-pharmaceutical-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2023First study: phase 1 study in Pleural Effusion, MalignantNew to JemincareJemincare · NCT05923515 · 78 planned · China
  2. Dec 13, 2024Phase 1 study in Pleural Effusion, MalignantJemincare · NCT06740019 · 30 planned · China
  3. Jun 10, 2026Shanghai Jeyou Pharmaceutical's first study: phase 2 study in Pleural Effusion, MalignantNew to Shanghai Jeyou PharmaceuticalShanghai Jeyou Pharmaceutical · NCT07649369 · 120 planned · China

Ahead

  1. Jan 12, 2028Primary completion: phase 2 study in Pleural Effusion, MalignantShanghai Jeyou Pharmaceutical · NCT07649369

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07649369Pleural Effusion, Malignant · China2Not yet recruitingShanghai Jeyou PharmaceuticalJan 12, 2028120
NCT06740019Pleural Effusion, Malignant · China1RecruitingJemincareDec 31, 202530
NCT05923515Pleural Effusion, Malignant · China1RecruitingJemincareApr 30, 202578

How it is read

Names in the registry

  • “JMKX000197”, 3 entries

Codes read as this program: JMKX000197.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.